Immunohistochemistry or IHC
Prognostic value and clinical significance of tumoral PD-L1 and stromal α-SMA expression in diffuse pleural mesothelioma
Neoplasma 2026 February [Link] Yeqi Sun, Lan Li, Lei Cai, Jihua Yang, Jun Qian, Fajiu Wang, Lifeng Wang Abstract Diffuse pleural mesothelioma (PM) is a rare malignant neoplasm with an extremely poor prognosis. Prognostic assessment remains challenging, highlighting the urgent need for reliable biomarkers to guide precise and effective therapy. Programmed death ligand 1 (PD-L1)…
Read MoreCytopathologic Features of Metastatic Malignant Mesothelioma With SMARCB1 (INI-1) Deficient Diagnosed by Ultrasound-Guided Fine-Needle Aspiration: A Case Report
Diagnostic Cytopathology 2025 December 29 [Link] Jun Yang, Juandi Liu, Jing Jin, Deng Pan, Lei Shao Abstract Malignant mesothelioma (MM) is a rare yet aggressive neoplasm that arises from mesothelial cells lining the thoracic and abdominal cavities, the pericardium, and the tunica testis. Characterized by rapid progression, high invasiveness, and a poor prognosis, MM poses…
Read MoreCytopathologic Features of Metastatic Malignant Mesothelioma With SMARCB1 (INI-1) Deficient Diagnosed by Ultrasound-Guided Fine-Needle Aspiration: A Case Report
Diagnostic Cytopathology 2025 December 29 [Link] Jun Yang, Juandi Liu, Jing Jin, Deng Pan, Lei Shao Abstract Malignant mesothelioma (MM) is a rare yet aggressive neoplasm that arises from mesothelial cells lining the thoracic and abdominal cavities, the pericardium, and the tunica testis. Characterized by rapid progression, high invasiveness, and a poor prognosis, MM poses…
Read MoreMerlin Immunohistochemistry Is Useful in the Differential Diagnosis of Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia
Pathology International 2026 January [Link] Kohei Aoe, Kei Kushitani, Vishwa Jeet Amatya, Tetsuya Nakagiri, Yoshihiro Miyata, Morihito Okada, Yukio Takeshima Abstract The differential diagnosis of epithelioid mesothelioma and reactive mesothelial hyperplasia can be challenging based on morphology alone, particularly in small specimens. Consequently, the use of ancillary techniques, such as immunohistochemistry for BRCA1-associated protein 1,…
Read MoreDiagnostic potential of a novel immunohistochemical marker, GFPT2, in differentiating mesothelioma from its morphological mimics
Histopathology 2025 December 15 [Link] Jia Wei, Xiaofang Ma, Gang Chen, Yan Wang, Qinhe Fan, Qixing Gong Abstract Aims: Mesothelioma (MESO) is a rare and aggressive tumour originating from mesothelial cells, primarily affecting the pleura and peritoneum. Its diagnosis remains challenging due to non-specific clinical, radiological and histopathological features, compounded by morphological diversity and overlapping…
Read MorePleural Mesothelioma Diagnosis for the Pulmonologist: Steps Along the Way
Cancers 2025 December 1 [Link] Alberto Fantin, Nadia Castaldo, Ernesto Crisafulli, Giulia Sartori, Filippo Patrucco, Horiana B Grosu, Paolo Vailati, Giuseppe Morana, Vincenzo Patruno, Stefano Kette, Avinash Aujayeb, Aleš Rozman Abstract Background/Objectives: Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis and complex diagnostic pathways. Pulmonologists often play a central role…
Read MoreTargeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatin
Cancer Research Communications 2025 December 10 [Link] Pınar Çakılkaya, Ida Marie Egeland Larsen, Qun Jiang, Kirstine Sandal Nørregaard, Henrik Gårdsvoll, Jingli Zhang, Henrik Jessen Jürgensen, Michaela Hansen Blomquist, Alba Martinez Perlado, Oliver Krigslund, Eric Santoni-Rugiu, Lars Henning Engelholm, Raffit Hassan, Niels Behrendt Abstract uPARAP is a collagen-internalizing receptor with emerging relevance as a therapeutic target.…
Read MoreMultiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype
Journal of Thoracic Oncology 2025 November 28 [Link] David T Severson, Samuel Freyaldenhoven, Benjamin Wadowski, Yin P Hung, Travis Hughes, Beow Y Yeap, William G Richards, Sanna Laaksonen, Lucian Chirieac, Matthew B Couger, Roderick V Jensen, Ahmed A Sadek, Ilkka Ilonen, Kimberly Vermilya, Simona Innocenti, Stephanie L Korle, Julianne S Barlow, Jamie Anderson, Jason Meyerovitz,…
Read MoreA novel malignant mesothelioma organoids-T cell co-culture platform for personalized immunochemotherapy testing
Scientific Reports 2025 November 21 [Link] Yang Liu, Yang Yang, Songlin An, Hua Wan, Minghao Zhang, Ruihong Yin, Weiting Zhao, Li Huang, Yunshan Zhao, Chenggang Li Abstract Malignant mesothelioma (MM) is a rare, aggressive cancer with poor outcomes due to its heterogeneity and therapy resistance. Patient-derived organoids (PDOs) have emerged as a promising tool for…
Read MorePD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma
Translational Lung Cancer Research 2025 September 30 [Link] Masatoshi Kanayama, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Hiroki Matsumiya, Masataka Mori, Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka Abstract Background: Pleural mesothelioma (PM) is an uncommon malignancy with a poor prognosis, even after surgical resection. Programmed death-ligand 1 (PD-L1) expression is a potential prognostic biomarker in various…
Read More
Skip to content